Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.
Angiogenesis Inhibitors
/ pharmacology
Animals
Apoptosis
Bevacizumab
/ pharmacology
Cell Proliferation
Female
High-Throughput Screening Assays
/ methods
Humans
Neoplasm Metastasis
Neovascularization, Pathologic
/ drug therapy
Triple Negative Breast Neoplasms
/ drug therapy
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Zebrafish
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
10 06 2020
10 06 2020
Historique:
received:
03
09
2019
accepted:
12
05
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
16
6
2021
Statut:
epublish
Résumé
Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending on the individual tumor, anti-VEGF therapies can either block or promote metastasis. In this context, an assay able to predict individual responses prior to treatment, including the impact on metastasis would prove of great value to guide treatment options. Here we show that zebrafish xenografts are able to reveal different responses to bevacizumab in just 4 days, evaluating not only individual tumor responses but also the impact on angiogenesis and micrometastasis. Importantly, we perform proof-of-concept experiments where clinical responses in patients were compared with their matching zebrafish Patient-Derived Xenografts - zAvatars, opening the possibility of using the zebrafish model to screen bevacizumab therapy in a personalized manner.
Identifiants
pubmed: 32523131
doi: 10.1038/s42003-020-1015-0
pii: 10.1038/s42003-020-1015-0
pmc: PMC7286887
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
299Subventions
Organisme : Howard Hughes Medical Institute
ID : MGF
Pays : United States
Références
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
doi: 10.1016/j.cell.2011.02.013
Ranieri, G. et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 13, 1845–1857 (2006).
pubmed: 16842197
doi: 10.2174/092986706777585059
Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).
pubmed: 29126136
doi: 10.1093/nar/gkx1037
Montero, A. J., Escobar, M., Lopes, G., Glück, S. & Vogel, C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr. Oncol. Rep. 14, 1–11 (2012).
pubmed: 22012632
pmcid: 3266439
doi: 10.1007/s11912-011-0202-z
Cardoso, F. et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol. 29, 1634–1657 (2018).
pubmed: 30032243
doi: 10.1093/annonc/mdy192
Goldfarb, S. B., Hudis, C. & Dickler, M. N. Bevacizumab in metastatic breast cancer: when may it be used? Ther. Adv. Med. Oncol. 3, 85–93 (2011).
pubmed: 21789158
pmcid: 3126041
doi: 10.1177/1758834010397627
Schuster, C. et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE 7, e38364 (2012).
pubmed: 22719881
pmcid: 3376108
doi: 10.1371/journal.pone.0038364
Wenger, K. J. et al. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol. Lett. 14, 1141–1146 (2017).
pubmed: 28693286
pmcid: 5494648
doi: 10.3892/ol.2017.6251
Eskens, F. A. L. M. & Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur. J. Cancer 42, 3127–3139 (2006).
pubmed: 17098419
doi: 10.1016/j.ejca.2006.09.015
Brandes, A. A., Bartolotti, M., Tosoni, A., Poggi, R. & Franceschi, E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20, 166–175 (2015).
pubmed: 25568148
pmcid: 4319633
doi: 10.1634/theoncologist.2014-0330
Goel, H. L. & Mercurio, A. M. VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871–882 (2013).
pubmed: 24263190
pmcid: 4011842
doi: 10.1038/nrc3627
Wanami, L. S., Chen, H.-Y., Peiró, S., García de Herreros, A. & Bachelder, R. E. Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp. Cell Res. 314, 2448–2453 (2008).
pubmed: 18554584
pmcid: 2762866
doi: 10.1016/j.yexcr.2008.05.004
Mak, P. et al. ERB impedes prostate cancer EMT by destabilizing HIF-a and inhibiting VEGF-mediated snail nuclear localization: implications for gleason grading. Cancer Cell 17, 319–332 (2010).
pubmed: 20385358
pmcid: 2881822
doi: 10.1016/j.ccr.2010.02.030
Luo, M. et al. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin. Cancer Lett. 373, 1–11 (2016).
pubmed: 26805761
doi: 10.1016/j.canlet.2016.01.010
Lu, K. V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21–35 (2012).
pubmed: 22789536
pmcid: 4068350
doi: 10.1016/j.ccr.2012.05.037
Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592–603 (2008).
pubmed: 18650835
pmcid: 2874834
doi: 10.1038/nrc2442
Shaheen, R. M. et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59, 5412–5416 (1999).
pubmed: 10554007
Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306–314 (2000).
pubmed: 11005565
pmcid: 1550290
doi: 10.1038/sj.neo.7900102
Drevs, J. et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60, 4819–4824 (2000).
pubmed: 10987292
Kim, L. S., Huang, S., Lu, W., Lev, D. C. & P, J. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 21, 107–118 (2004).
pubmed: 15168728
doi: 10.1023/B:CLIN.0000024761.00373.55
Ebos, J. M. L. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
pubmed: 19249681
pmcid: 4540346
doi: 10.1016/j.ccr.2009.01.021
Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
pubmed: 19249680
pmcid: 2874829
doi: 10.1016/j.ccr.2009.01.027
Gonzalez-Moreno, O. et al. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp. Cell Res. 316, 554–567 (2010).
pubmed: 20006606
doi: 10.1016/j.yexcr.2009.11.020
Beck, B. et al. A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399–403 (2011).
pubmed: 22012397
doi: 10.1038/nature10525
Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. 108, 3749–3754 (2011).
pubmed: 21321221
doi: 10.1073/pnas.1014480108
Cao, Y. et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72, 3912–3918 (2012).
pubmed: 22693250
pmcid: 3427728
doi: 10.1158/0008-5472.CAN-11-4058
Hong, J. P., Li, X. M., Li, M. X. & Zheng, F. L. VEGF suppresses epithelial-mesenchymal transition by inhibiting the expression of Smad3 and miR-192, a Smad3-dependent microRNA. Int. J. Mol. Med. 31, 1436–1442 (2013).
doi: 10.3892/ijmm.2013.1337
Deng, Y. R., Liu, W. B., Lian, Z. X., Li, X. & Hou, X. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget 7, 38292–38305 (2016).
pubmed: 27203677
pmcid: 5122390
doi: 10.18632/oncotarget.9438
Jang, H. J., Kim, B. J., Kim, J. H. & Kim, H. S. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget 8, 73009–73016 (2017).
pubmed: 29069844
pmcid: 5641187
doi: 10.18632/oncotarget.20314
Yan, C. et al. Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish. Cell (2019). https://doi.org/10.1016/j.cell.2019.04.004 .
Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl Acad. Sci. 201618389 (2017). https://doi.org/10.1073/pnas.1618389114 .
Veinotte, C. J., Dellaire, G. & Berman, J. N. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis. Model. Mech. 7, 745–754 (2014).
pubmed: 24973744
pmcid: 4073264
doi: 10.1242/dmm.015784
Haldi, M. et al. Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9, 139–151 (2006).
pubmed: 17051341
doi: 10.1007/s10456-006-9040-2
Marques, I. J. et al. Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 9, 128 (2009).
pubmed: 19400945
pmcid: 2697170
doi: 10.1186/1471-2407-9-128
Stoletov, K. et al. Visualizing extravasation dynamics of metastatic tumor cells. J. Cell Sci. 123, 2332–2341 (2010).
pubmed: 20530574
pmcid: 2886748
doi: 10.1242/jcs.069443
Nicoli, S., Ribatti, D., Cotelli, F. & Presta, M. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res. 67, 2927–2931 (2007).
pubmed: 17409396
doi: 10.1158/0008-5472.CAN-06-4268
Goishi, K. & Klagsbrun, M. B. Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development. in Developmental vascular biology, 62, 127–152 (Academic Press, 2004).
Chavez, K. J., Garimella, S. V. & Lipkowitz, S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35–48 (2010).
pubmed: 21778573
pmcid: 3532890
doi: 10.3233/BD-2010-0307
Hewitt, R. E. et al. Validation of a model of colon cancer progression. J. Pathol. 192, 446–454 (2000).
pubmed: 11113861
doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH775>3.0.CO;2-K
Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307–318 (2002).
pubmed: 12167406
doi: 10.1006/dbio.2002.0711
Prall, F., Gringmuth, U., Nizze, H. & Barten, M. Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival. Histopathology 42, 482–491 (2003).
pubmed: 12713626
doi: 10.1046/j.1365-2559.2003.01610.x
Couvelard, A. et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 46, 668–676 (2005).
pubmed: 15910598
doi: 10.1111/j.1365-2559.2005.02160.x
European Medicines Agency (EMA). Assessment report. EMA/97237/2019, Committee for Medicinal Products for Human Use, Vol. 44 (2019).
Liu, Y. et al. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest. N. Drugs 32, 851–859 (2014).
doi: 10.1007/s10637-014-0129-y
Mésange, P. et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 5, 4709–4721 (2014).
pubmed: 25015210
pmcid: 4148093
doi: 10.18632/oncotarget.1671
Plantamura, I. et al. PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Mol. Oncol. 8, 968–981 (2014).
pubmed: 24747080
pmcid: 5528530
doi: 10.1016/j.molonc.2014.03.015
Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427 (2011).
pubmed: 21629292
doi: 10.1038/nrd3455
Traver, D. et al. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat. Immunol. 4, 1238–1246 (2003).
pubmed: 14608381
doi: 10.1038/ni1007
Nguyen, D. X., Bos, P. D. & Massagué, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274 (2009).
pubmed: 19308067
doi: 10.1038/nrc2622
Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275–292 (2011).
pubmed: 22000009
pmcid: 3261217
doi: 10.1016/j.cell.2011.09.024
Elbos, J. & Kerbel, R. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis John. Nat. Rev. Clin. Oncol. 8, 210–221 (2015).
doi: 10.1038/nrclinonc.2011.21
White, R. M. et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2, 183–189 (2008).
pubmed: 18371439
pmcid: 2292119
doi: 10.1016/j.stem.2007.11.002
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772
pmcid: 22743772
doi: 10.1038/nmeth.2019
Tischer, C. & Tosi, S. Tumor blood vessels_ 3D tubular network analysis. in Bioimage data analysis (ed Miura, K.) Ch. 9 (Wiley, 2016).